ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of$ 0.12. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this company would post a loss of$ 0.11 per share when it actually produced a loss of $0.11, delivering no surprise. Over the last four quarters, the company has surpa ...